【辉瑞抗病毒药物瑞派乐® 获常规批准,用于新冠重症高风险人群抗感染治疗】金十数据3月25日讯,近日,辉瑞抗病毒药物瑞派乐®(英文商品名称:PAXLOVID®,药品通用名称:奈玛特韦片/利托那韦片组合包装)获国家药品监督管理局常规批准,用于治疗成人伴有进展为重症高风险因素的轻至中度新型冠状病毒感染(COVID-19)患者1。瑞派乐®于2022年2月由国家药品监督管理局按照药品特别审批程序,应急审评审批,获得附条件批准。辉瑞按照国家药品监督管理局要求,继续开展相关研究工作,完成了附条件要求后,基于研究结果获得常规批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.